1. Welsch, C.W. and H. Nagasawa, Prolactin and murine mammary tumorigenesis: a review. Cancer Res., 1977. 37: p. 951-963.

2. Vonderhaar, B.K. and R. Biswas, Prolactin effects and regulation of its receptors in human mammary tumor cells, in Cellular and Molecular Biology of Mammary Cancer, D. Medina, et al., Editors. 1987, Plenum Publishing Corp.: New York, NY. p. 205-219.

3. Kelly, P.A., et al., The prolactin/growth hormone receptor family. Endocrine Rev., 1991. 12: p. 235-251.

4. Lesueur, L., et al., Comparison of long and short forms of the prolactin receptor on prolactin-induced milk protein gene transcription. Proc. Natl. Acad. Sci. USA, 1991. 88: p. 482-828.

5. Berlanga, J.J., et al., The short form of the prolactin (PRL) receptor silences PRL induction of the beta-casein gene promoter. Mol. Endocrinol., 1997. 11: p. 1449-57.

6. Das, R. and B.K. Vonderhaar, Transduction of prolactin's growth signal through both the long and short forms of the prolactin receptor. Mol. Endocrinol., 1995. 9: p. 1750-1759.

7. O'Neal, K.D. and L. Yu Lee, Differential signal transduction of the short, Nb2, and long prolactin receptors. J. Biol. Chem., 1994. 269: p. 26076-26082.

8. Codegone, M.L., et al., Histology and cytometrics in human breast cancers assayed for the presence of prolactin receptors. Tumori, 1981. 67: p. 549-552.

9. Peyrat, J.P., et al., Total prolactin binding sites in human breast cancer biopsies. Breast Cancer Res. Treat., 1981. 1: p. 369-373.

10. Bonneterre, J., et al., Prolactin receptors in human breast cancer. Eur. J. Cancer Clin. Oncol., 1982. 18: p. 1157-1162.

11. L'Hermite-Baleriaux, M., et al., Prolactin and prolactin receptors in human breast disease. Prog. Cancer Res. Therapy, 1984. 31: p. 325-334.

12. Goffin, V. and P.A. Kelly, The prolactin/growth hormone receptor family: structure/function relations. J. Mammary Gland Biol. Neoplasia, 1997. 2: p. 7-17.

13. Ginsburg, E. and B.K. Vonderhaar, Prolactin synthesis in human breast cancer cells is irrelevant to ER status. 1997. submitted.

14. Clevenger, C.V., et al., Expression of prolactin and prolactin receptor in human breast carcinoma. Am. J. Pathol., 1995. 146: p. 695-705.

15. Mertani, H.C., et al., Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer, 1998. in press.

16. Vonderhaar, B.K., Hormones and growth factors in mammary gland development, in Control of Cell Growth and Proliferation, C.M. Veneziale, Editor. 1984, Van Noostrand, Reinhold and Co., Inc.: New York, N.Y. p. 11-33.

17. Vonderhaar, B.K., Prolactin: transport, function, and receptors in mammary gland development and differentiation, in The Mammary Gland, M.C. Neville and C.W. Daniel, Editors. 1987, Plenum Publishing Corporation: New York, NY. p. 383-438.

18. Nagasawa, H., et al., Interrelationship between prolactin and progesterone in normal mammary gland growth in SHN virgin mice. Exp. Clin. Endocrinol., 1985. 86: p. 357-360.

19. McManus, M.J. and C.W. Welsch, The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer, 1984. 54: p. 1920-1927.

20. Malarkey, W.B., et al., Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J. Clin. Endocrinol. Metab., 1983. 56: p. 673-677.

21. Biswas, R. and B.K. Vonderhaar, Role of serum in prolactin responsiveness of MCF-7 human breast cancer cells in long term tissue culture. Cancer Res., 1987. 47: p. 3509-3514.

22. Vonderhaar, B.K., Prolactin: The forgotten hormone of human breast cancer. Pharm. Ther., 1998. in press.

23. Lemus-Wilson, A., P.A. Kelly, and D.E. Blask, Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. British J. Cancer, 1995. 72: p. 1435-1440.

24. Das, R., E. Ginsburg, and B.K. Vonderhaar, Tamoxifen as an antilactogen in human breast cancer cells., in Proceedings of the International Cancer Congress, R.S. Rao, et al., Editors. 1994, Monduzzi Editore, Inc.: Bologna. p. 1487-1491.

25. Das, R., et al., Tamoxifen and ICI 182780 inhibit PRL-induced growth of ER+ and ER- human breast cancer cells. Cancer Res., 1997. in press.

26. Lochnan, H.A., et al., Functional activity of the human prolactin receptor and its ligands. Mol. Cell. Endocrinol., 1995. 114: p. 91-99.

27. Purnell, D.M., et al., Immunoreactive prolactin in epithelial cells of normal and cancerous human breast and prostate detected by the unlabeled antibody peroxidase-antiperoxidase method. Cancer Res., 1982. 42: p. 2317-2324.

28. Agarwal, P.K., et al., Highly specific sites of prolactin binding in benign and malignant breast disease. Indian J. Exper. Biol., 1989. 27: p. 1035-1038.

29. Wang, D.Y., et al., Serum prolactin levels in women with breast cancer and their relationship to survival. Eur. J. Cancer Clin. Oncol., 1986. 22: p. 487-492.

30. Ingram, D.M., E.M. Nottage, and A.N. Roberts, Prolactin and breast cancer risk. Med. J. Australia, 1990. 153: p. 469-473.

31. Love, R.R., et al., Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. Cancer, 1991. 68: p. 1401-1405.

32. DePlacido, S., et al., Prolactin receptor does not correlate with oeastrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results on the Naples adjuvant (GUN) study. Br. J. Cancer, 1990. 62: p. 643-646.

33. Henson, J.C., A. Coune, and M. Staquet, Clinical trial of 2-Br-a-ergocryptine (CB154) in advanced breast cancer. Eur. J. Cancer, 1972. 8: p. 155 - 156.

34. Pearson, O.H. and A. Manni, Hormonal control of breast cancer growth in women and rats, in Current Topics in Experimental Endocrinology, L. Martini and V.H.T. James, Editors. 1978, Academic Press: New York. p. 75-92.

35. Manni, A., et al., Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res. Treat., 1989. 14: p. 289-298.

36. Anderson, E., et al., Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octeotide. Eur. J. Cancer, 1993. 29A: p. 209-217.

37. Ben-Jonathan, N., et al., Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Rev., 1996. 17: p. 639-669.

38. Lachelin, G.C.L., S.S.C. Yen, and J.F. Alksne, Hormonal changes following hypophysectomy in humans. Obstet. Gynecol., 1977. 50: p. 333-339.

39. Clevenger, C.V., et al., Regulation of IL-2 -driven T-lymphocyte proliferation by prolactin. Proc. Natl. Acad. Sci. USA, 1990. 87: p. 6460-6464.

40. Gellerson, B., et al., Nonpituitary human prolactin gene transcription is independent of pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol. Endocrinol., 1994. 8: p. 356-373.

41. Sinha, Y.N., Structural variants of prolactin: occurrence and physiological significance. Endocrine Reviews, 1995. 16: p. 354-369.

42. Richards, R.G. and S.M. Hartman, Human dermal fibroblast cells express prolactin in vitro. J Invest Dermatol, 1996. 106: p. 1250-1255.

43. Steinmetz, R.W., A.L. Grant, and P.V. Malven, Transcription of prolactin gene in milk secretory cells of the rat mammary gland. J. Endocrinol., 1993. 36: p. 271-276.

44. Kurtz, A., et al., Mammary epithelial cells of lactating rats express prolactin messenger ribonucleic acid. Biol. Reproduction, 1993. 48: p. 1095-1103.

45. LeProvost, F., et al., Prolactin gene expression in ovine and caprine mammary gland. Neuroendocrinol., 1994. 60: p. 305-313.

46. Ginsburg, E. and B.K. Vonderhaar, Prolactin synthesis and secretion by human breast cancer cells. Cancer Res., 1995. 55: p. 2591-2595.

47. Ginsburg, E., R. Das, and B.K. Vonderhaar, Prolactin: An autocrine growth factor in the mammary gland, in Biological Signalling and the Mammary Gland, C.J. Wilde, M. Peaker, and E. Taylor, Editors. 1997, Hannah Research Institute: Ayr, Scotland UK. p. 47-58.

48. Bancroft, F.C. and A.H. Tashjian, Growth in suspension culture of rat pituitary cells which produce growth hormone and prolactin. Exp Cell Res, 1971. 64: p. 125-128.

49. Tanaka, T., et al., A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J. Clin. Endocrinol. Metab., 1980. 51: p. 1058-1063.

50. Markoff, E., et al., Glycosylation selectively alters the biological activity of prolactin. Endocrinol., 1988. 123: p. 1303-1306.

51. Lewis, U.L., R.N.P. Singh, and L.J. Lewis, Two forms of glycosylated prolactin have different pigeon crop sac-stimulating activities. Endocrinol., 1989. 124: p. 1558-1563.

52. Shaw-Bruha, C.M., S.J. Pirrucello, and J.D. Shull, Expression of the prolactin gene in normal and neoplastic human breast tissues and human mammary cell lines: promoter usage and alternative mRNA splicing. Breast Cancer Res. Treatment, 1997. 4: p. 243-253.

53. Fuh, G. and J.A. Wells, Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J. Biol. Chem., 1995. 270: p. 13133-13137.

54. Dattani, M.T., et al., G120R, a human growth hormone antagonist, shows zinc-dependent agonist and antagonist activity on Nb2 cells. J. Biol. Chem., 1995. 270: p. 9222-9226.

55. Mode, A., et al., The human growth hormone (hGH) antagonist G120RhGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor. Endocrinol., 1996. 137: p. 447-454.

56. Goffin, V., et al., Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J. Biol. Chem., 1996. 271: p. 16573-16579.

57. Peterson, F.C. and C.L. Brooks, Identification of a motif associated with the lactogenic actions of human growth hormone. J. Biol. Chem., 1997. 272: p. 21444-21448.